Trial Profile
Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 25 Oct 2023 Results (n=26) assessing safety and efficacy of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia published in the Blood
- 06 Jun 2023 Results (n=27) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 13 Mar 2023 Planned End Date changed from 28 Feb 2023 to 28 Feb 2025.